Toby Maher is Professor of Interstitial Lung Disease at the National Heart and Lung Institute at Imperial College London, UK, and practices as a pulmonologist at Royal Brompton Hospital, London. With a robust research background in idiopathic pulmonary fibrosis and connective-tissue-disease-associated ILD, he has been involved in over 45 fibrotic lung disease trials.
Naftali Kaminski, MD
Dr. Naftali Kaminski is the Boehringer-Ingelheim Endowed Professor of Internal Medicine and Chief of Pulmonary, Critical Care and Sleep Medicine at Yale School of Medicine. His research interests include applying genomic approaches to improve diagnosis and treatment of idiopathic pulmonary fibrosis and other chronic lung diseases.
Cara Williams, PhD
Cara Williams is a senior drug discovery scientific and R&D leader committed to identifying and developing next generation breakthrough therapies for IPF. Her preclinical drug discovery and development experience focuses on delivering both small molecule and large molecule drug candidates into clinical development across multiple therapeutic areas including respiratory diseases such as IPF, COPD, CF and asthma, immunological indications inflammatory disease, gastrointestinal diseases, dermatology and pain.